论文部分内容阅读
目的检测微小染色体维持蛋白7(MCM7)在子宫内膜腺癌组织中的表达,探讨其表达与子宫内膜腺癌临床病理参数的关系。方法应用免疫组化方法检测MCM7在单纯性增生子宫内膜、子宫内膜不典型增生和子宫内膜腺癌组织中的表达,以及雌激素受体(ER)、孕激素受体(PR)在子宫内膜腺癌中的表达。结果 MCM7在子宫内膜单纯性增生、不典型增生以及子宫内膜腺癌中的表达逐渐增高(P<0.05),在子宫内膜腺癌的表达与患者的年龄呈正相关(>45岁,P=0.007)、肿瘤的病理学分级呈负相关(P=0.0003),并进一步发现雌激素受体(ER)、孕激素受体(PR)阴性表达的肿瘤组织中MCM7表达高于受体阳性的肿瘤组织(P=0.002;P=0.021)。结论 MCM7在子宫内膜腺癌的发生发展过程中起促进作用,这一促进作用在雌孕激素受体阴性的子宫内膜腺癌更明显。
Objective To detect the expression of minichromosome maintenance protein 7 (MCM7) in endometrial adenocarcinoma and to explore its relationship with clinicopathological parameters of endometrial adenocarcinoma. Methods Immunohistochemistry was used to detect the expression of MCM7 in simple proliferative endometrium, endometrial dysplasia and endometrial adenocarcinoma, and the expressions of estrogen receptor (ER), progesterone receptor (PR) Endometrial adenocarcinoma expression. Results The expression of MCM7 in endometrial hyperplasia, atypical hyperplasia and endometrial adenocarcinoma was gradually increased (P <0.05). The expression of MCM7 was positively correlated with the age of the patients (> 45 years old, P = 0.007). The pathological grade of tumor was negatively correlated (P = 0.0003), and further found that the expression of MCM7 in estrogen receptor (ER) and progesterone receptor (PR) negative tissues was higher than that in receptor positive Tumor tissue (P = 0.002; P = 0.021). Conclusion MCM7 plays an important role in the development of endometrial adenocarcinoma. This promoting effect is more obvious in estrogen and progesterone receptor negative endometrial adenocarcinoma.